



新冠疫苗的“前世”与“今生”

重磅疫苗讲座与座谈！来自NIH的 Dr. Kizzmekia Corbett 专题讲座, 以及专家圆桌讨论会

目前全球施打的新冠疫苗包括美国辉瑞 (Pfizer/BioNTech) 和莫德纳 (Moderna) 的 mRNA 疫苗、英国阿斯利康、俄罗斯卫星五号的病毒载体疫苗以及中国国药和科兴的灭活疫苗。美国的两款 mRNA 疫苗已得到联邦食品与药物管理局 (FDA) 的紧急授权, 在美国大范围接种, 带来战胜新冠病毒的希望。然而, 很多民众对快速研发成功的新型疫苗持有诸多疑问。鉴于此, 美国华盛顿地区中国大专院校校友会联合会 (CAAGW) 和中科院上海生化细胞研究所海外联谊会 (SIBCB_OA) 将于 2021 年 1 月 30 日晚 8 时联合推出 “Featured Seminar and Discussion on COVID-19 Vaccines” 疫情讲座和讨论会。希望与会专家展示的科学数据、研发历程及讨论答疑能解除您心中的困惑。

本次讲座和讨论会将分两部分进行。第一部分为讲座 (Seminar)。负责 Moderna 新冠疫苗研发项目的美国国立卫生研究院疫苗研究中心 (NIH, VRC) 的 Dr. Kizzmekia Corbett 的学术报告题目为: “Rapid SARS-CoV-2 Vaccine Development”, 为您介绍 Moderna SARS-CoV-2 Vaccine 研发的详细过程。第二部分是 “Efficacy and Safety of COVID-19 Vaccines: Scientist’s Perspective” 为主题的研讨会。多位长期从事基础科学研究和在疫苗开发前沿的专家学者将和您共同探讨新冠疫苗的有效性和安全性。

Zoom meeting: Featured Seminar and Discussion on COVID-19 Vaccines

Part 1, Meet Dr. Kizzmekia Corbett, a leading scientist at the forefront of COVID-19 vaccine development

Seminar: Rapid SARS-CoV-2 Vaccine Development

Speaker: Kizzmekia S. Corbett, Ph.D.
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team

Viral Pathogenesis Laboratory | Vaccine Research Center
NIAID/NIH

Part 2, Efficacy and Safety of COVID-19 Vaccines: Scientists’ Perspective

Panelists:
Jinfang (Jeff) Zhu, Ph.D. Principal Investigator, Chief of Molecular and Cellular Immunoregulation Section, NIAID/NIH
Guang-Liang Wang, Ph.D. Senior Director, Cerevel Therapeutics

Qiang Yang, Ph.D. Founding partner and Research Director of GlycoT Therapeutics LLC
And other scholars from FDA and NIH
Time: 01/30/2021 (Saturday), 8:00pm-10:00pm (EST)

Join Zoom Meeting <https://us02web.zoom.us/j/84608612593>

Meeting ID: 846 0861 2593
One tap mobile
+ 13017158592, 84608612593# US

(Germantown)
+16468769923, 84608612593# US (New York)

View on YouTube: www.youtube.com/c/caagw

Organizers:
Chinese Alumni Associations of Greater Washington (CAAGW)

Shanghai Institute of Biochemistry and Cell Biology Oversea Association (SIBCB_OA)

Dr. Kizzmekia Corbett seminar’s abstract:

Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity. This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Following preclinical and early phase trials, mRNA-1273 has been deemed 94.1% effective and safe and is currently under emergency use.

Speaker Biography



Dr. Kizzmekia Corbett is current a Senior Research Fellow and Scientific Lead Coronavirus Vaccines & Immunopathogenesis (coVip) Team at Vaccine Research Center (VRC), National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). She is a viral immunologist focused on elucidating mechanisms of viral pathogenesis and host immunity to propel the advancement of novel vaccines.

Corbett received a B.S. in Biological Sciences, with a secondary major in Sociology, in 2008 from the University of Maryland - Baltimore County, then got her Ph.D. in



图片配文: 美国国家卫生研究院冠状病毒疫苗研究的首席科学家 Dr. Kizzmekia Corbett, 一位年仅 34 岁的非裔女性科学家, 被媒体赞为研发冠状病毒疫苗的领头羊

Microbiology and Immunology in 2014 at University of North Carolina at Chapel Hill. She was appointed to the VRC, NIH in 2014.



Dr. Kizzmekia Corbett (left) a senior virus researcher with Dr. Anthony Fauci, NIH director Dr. Francis Collins and Former Pres. Trump. Corbett is praised as key scientist behind COVID-19 vaccine.

Dr. Corbett is one of the National Institutes of Health’s leading scientists behind the government’s search for a vaccine. To manufacture and test the COVID-19 vaccine Corbett’s team partnered with Moderna, a biotechnology company, to rapidly enter animal studies. Subsequently, the vaccine (named mRNA-1273) entered Phase 1 clinical trial only 66 days after the virus sequence was released. Following preclinical and early phase trials, mRNA-1273 has been deemed 94.1% effective and safe and is currently under emergency use.

“Kizzy is an African American scientist who is right at the forefront of the development of the vaccine. She is a scientist who is right at the forefront of the development of the vaccine,” Dr. Fauci related.

“Dr. Corbett is someone who will go down in history as one of the key players in developing the science that could end the pandemic.”



Dr. Kizzmekia Corbett praised as key scientist behind COVID-19 vaccine. Fauci praised, “Kizzy is an African American scientist who is right at the forefront of the development of the vaccine.”

Vice President Kamala D. Harris, praised Corbett on Twitter, saying she was “leading the charge all the time to develop a vaccine for coronavirus. The world owes you and your team a debt of gratitude.”



According to December 11, 2020 Vol. LXXII, No. 25 “NIH RECORD”, Long before Covid-19 became a global crisis, scientists at NIH’s Vaccine Research Center were examining the fundamental mechanics of coronaviruses. Already the world had witnessed the damage SARS and MERS could do, and veteran virologists knew it was only a matter of time before the next threat emerged. VRC investigators had devised a strategy, however, and their proactive research provided a much-needed jumpstart in the race for a vaccine.

Recounting those efforts, Dr. Kizzmekia Corbett, a senior research fellow who’s spent the past 6 years working with VRC strategists in NIAID’s Viral Pathogenesis Laboratory (VPL) and who’s become a central figure in covid vaccine science, recently discussed “SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.”



“The reason that I started to work in coronavirus was not to ever develop a vaccine, but really to have such a strong understanding in vaccine immune responses that we could potentially develop one,” she said in her social media.

未完下接 25 版